Ruboxistaurin
From Infogalactic: the planetary knowledge core
File:Ruboxistaurin.svg | |
Ball-and-stick model of the ruboxistaurin molecule | |
Systematic (IUPAC) name | |
---|---|
(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione
|
|
Identifiers | |
CAS Number | 169939-94-0 |
ATC code | none |
PubChem | CID: 153999 |
IUPHAR/BPS | 5263 |
ChemSpider | 135727 |
UNII | 721809WQCP |
ChEMBL | CHEMBL91829 |
Chemical data | |
Formula | C28H28N4O3 |
Molecular mass | 468.546 g/mol |
|
|
(what is this?) (verify) |
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2]
Mechanism of action
Ruboxistaurin is an inhibitor of protein kinase C-beta.[3]
References
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Eli Lilly and Company
- Bisindolylmaleimides
- Gastrointestinal system drug stubs